Principal Financial Group’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-115,487
| Closed | -$2.47M | – | 2447 |
|
|
2023
Q2 | $2.47M | Sell |
115,487
-6,116
| -5% | -$180K | ﹤0.01% | 1726 |
|
|
2023
Q1 | $4.92M | Sell |
121,603
-795
| -0.6% | -$38K | ﹤0.01% | 1533 |
|
|
2022
Q4 | $5.69M | Sell |
122,398
-5,117
| -4% | -$233K | ﹤0.01% | 1491 |
|
|
2022
Q3 | $6.61M | Sell |
127,515
-2,496
| -2% | -$146K | 0.01% | 1388 |
|
|
2022
Q2 | $6.15M | Buy |
130,011
+7,243
| +6% | +$393K | ﹤0.01% | 1481 |
|
|
2022
Q1 | $8.74M | Buy |
122,768
+507
| +0.4% | +$33K | 0.01% | 1448 |
|
|
2021
Q4 | $9.14M | Sell |
122,261
-4,409
| -3% | -$346K | 0.01% | 1446 |
|
|
2021
Q3 | $7.2M | Sell |
126,670
-2,292
| -2% | -$113K | ﹤0.01% | 1551 |
|
|
2021
Q2 | $5.68M | Buy |
128,962
+1,109
| +0.9% | +$54.3K | ﹤0.01% | 1676 |
|
|
2021
Q1 | $6.31M | Buy |
127,853
+773
| +0.6% | +$38.6K | ﹤0.01% | 1587 |
|
|
2020
Q4 | $5.35M | Sell |
127,080
-4,713
| -4% | -$207K | ﹤0.01% | 1535 |
|
|
2020
Q3 | $6.03M | Buy |
131,793
+6,560
| +5% | +$318K | 0.01% | 1368 |
|
|
2020
Q2 | $6.29M | Buy |
125,233
+980
| +0.8% | +$50.7K | 0.01% | 1327 |
|
|
2020
Q1 | $6.39M | Sell |
124,253
-4,855
| -4% | -$259K | 0.01% | 1150 |
|
|
2019
Q4 | $7.98M | Buy |
129,108
+3,364
| +3% | +$209K | 0.01% | 1362 |
|
|
2019
Q3 | $7.55M | Sell |
125,744
-2,038
| -2% | -$151K | 0.01% | 1353 |
|
|
2019
Q2 | $10.8M | Sell |
127,782
-10,425
| -8% | -$938K | 0.01% | 1176 |
|
|
2019
Q1 | $13.2M | Buy |
138,207
+1,038
| +0.8% | +$93.1K | 0.01% | 1055 |
|
|
2018
Q4 | $9.72M | Sell |
137,169
-2,355
| -2% | -$181K | 0.01% | 1192 |
|
|
2018
Q3 | $11.9M | Buy |
139,524
+15,112
| +12% | +$1.51M | 0.01% | 1223 |
|
|
2018
Q2 | $14.4M | Buy |
124,412
+10,888
| +10% | +$1.09M | 0.01% | 1057 |
|
|
2018
Q1 | $9.19M | Buy |
113,524
+3,565
| +3% | +$274K | 0.01% | 1296 |
|
|
2017
Q4 | $6.45M | Buy |
109,959
+1,735
| +2% | +$86.9K | 0.01% | 1472 |
|
|
2017
Q3 | $5.07M | Buy |
108,224
+1,971
| +2% | +$79.2K | ﹤0.01% | 1550 |
|
|
2017
Q2 | $3.82M | Buy |
106,253
+15
| +0% | +$480 | ﹤0.01% | 1626 |
|
|
2017
Q1 | $3.27M | Buy |
106,238
+3,713
| +4% | +$116K | ﹤0.01% | 1650 |
|
|
2016
Q4 | $3.44M | Buy |
102,525
+1,347
| +1% | +$38.6K | ﹤0.01% | 1628 |
|
|
2016
Q3 | $2.69M | Buy |
101,178
+7,701
| +8% | +$179K | ﹤0.01% | 1631 |
|
|
2016
Q2 | $2.06M | Buy |
93,477
+2,652
| +3% | +$69.4K | ﹤0.01% | 1650 |
|
|
2016
Q1 | $2.67M | Buy |
90,825
+4,504
| +5% | +$125K | ﹤0.01% | 1562 |
|
|
2015
Q4 | $2.85M | Buy |
86,321
+3,795
| +5% | +$124K | ﹤0.01% | 1553 |
|
|
2015
Q3 | $2.98M | Buy |
+82,526
| New | +$3.54M | ﹤0.01% | 1543 |
|
Other funds holding ENTA
AC
FCM
B
KAM
Principal Financial Group's ENTA Position: Q3 2023 in Review
Principal Financial Group sold out of Enanta Pharmaceuticals (ENTA) in Q3 2023, closing a stake of 115,487 shares — an estimated $2.47M sold.
Principal Financial Group first reported a position in ENTA in Q3 2015 and held it in 32 quarters. The position peaked at $14.4M in Q2 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q3 2023.
- Principal Financial Group reported no remaining Enanta Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
- Principal Financial Group sold 115,487 Enanta Pharmaceuticals shares in Q3 2023, an estimated $2.47M.
- Principal Financial Group first reported a position in Enanta Pharmaceuticals in Q3 2015 and held it in 32 quarters.
- Principal Financial Group's Enanta Pharmaceuticals position peaked at $14.4M in Q2 2018.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2023.
Based on Principal Financial Group's 13F filing for Q3 2023, filed 2 Nov 2023.